

Online Research @ Cardiff

This is an Open Access document downloaded from ORCA, Cardiff University's institutional repository: <https://orca.cardiff.ac.uk/96170/>

This is the author's version of a work that was submitted to / accepted for publication.

Citation for final published version:

Lee, Paul Yuh Feng, Kwan, Alvin P.L., Smith, Paul and Nokes, Leonard 2016. Should we treat soft tissue injuries with Actovegin. *EC Orthopaedics* 4 (4) , pp. 600-604. file

Publishers page: <https://www.econicon.com/ecor/pdf/ECOR-04-0000102...>
<<https://www.econicon.com/ecor/pdf/ECOR-04-0000102.pdf>>

Please note:

Changes made as a result of publishing processes such as copy-editing, formatting and page numbers may not be reflected in this version. For the definitive version of this publication, please refer to the published source. You are advised to consult the publisher's version if you wish to cite this paper.

This version is being made available in accordance with publisher policies.

See

<http://orca.cf.ac.uk/policies.html> for usage policies. Copyright and moral rights for publications made available in ORCA are retained by the copyright holders.



Title:

Should we treat soft tissue injuries with Actovegin?

Running head: Actovegin - medicine or doping?

Dr. Paul Lee

MBBch, MFSEM, MSc, PhD, FEBOT, FRCS (T&O)

Dr. Alvin Kwan

BSc, PhD

Dr Paul M. Smith

BSc, MSc, PhD

Prof. Len Nokes

BEng, MSc, PhD, MBBCh, MD, FIMechE, CEng, PgDipSEM, FFSEM

Corresponding Authors:

Paul Lee

Postal address:

Health Technology and Digital World

Actovegin Research Group

Cardiff School of Engineering

Cardiff University

Queen's Buildings

The Parade

CARDIFF CF24 3AA

Wales, UK

Mobile: +44 7764614688

Email address: paul@welshbone.com

Acknowledgments:

no financial support, financial interest or benefit is received for this work by any of the authors

Abstract:

Actovegin is a biological drug produced from deproteinised hemodialysate of calf serum with over 50 years of history for its clinical use. There have been many *in vitro* studies to speculate its potential role and mechanism of action in cells; due to the nature of this drug and serum based culture techniques for most *in vitro* experiments, presumptuous conclusions and claims from these studies on performance enhancement should be cautiously interpreted. There have been well-designed human *in vivo* studies suggesting it does not enhance human performance, and has potentially good clinical applications to treat injuries, strokes and diabetes. Recently, evidence has emerged suggesting Actovegin has anti-inflammatory and anti apoptotic effects on injured tissues; further clinical research is needed to define these effects. This article also provides a narrative review of Actovegin summarizing outcomes from recent publications.

Abstract Word count: 136**Keywords**

Actovegin, doping, soft tissue injury, treatment, sports, orthopaedics

Muscle injuries are common in sport and are best treated using a regime of rest, immobilization, compression and physical therapy[7]. However, this so-called “knowledge” is based upon long-standing convention and expert opinion, which at best could be classified as level 4 evidence. It has been suggested that injection therapy might have a role to play in the treatment of muscle injuries[7,14]. Different treatment options such as growth factors have been explored and have demonstrated encouraging therapeutic results[7]. However, due to anabolic properties, treatment approaches incorporating growth factors, autologous blood and autologous conditioned serum are prohibited by the World Anti-Doping Agency (WADA)[22].

Injection Therapy

Recent developments in Sports Medicine have led to many substances being used in the context of injection therapy[11]. Platelet rich plasma (PRP) and autologous conditioning serum (ACS) have become popular substances of choice for injection therapies – it is alleged that such treatments facilitate muscle healing by optimizing provision of growth factors involved in the regeneration of muscle, as demonstrated by several animal studies[12,13,16]. A recent double-blind, randomized controlled trial by Reurink et al found that there were no statistical or clinical differences between their PRP and placebo groups in the treatment of muscle injuries[16]. Further, there are currently no universally accepted PRP preparation protocols to ensure consistent concentration and quality control between individual injections. The principle of using blood products as a drug to treat muscle is not new, as biological drugs form a major part of pharmaceutical drug development. As medicine has evolved and scientific knowledge continues to develop, a number of “older drugs” could be used in the effective treatment of acute muscle injuries.

Actovegin

Actovegin (Takeda Pharmaceutical Company Ltd, Osaka, Japan) is a biological drug produced from deproteinised haemodialysate of calf serum with a high standard of quality control. (figure 1) There are over 50 years of history for its clinical use with much *in-vitro* as well as clinical evidence to support its efficacy[1]. Indeed, the role of calf blood derivatives have a well established role in the maintenance of cellular viability and survival *in vitro*, for example, it is commonly used in the form of foetal bovine serum (FBS) supplement in tissue

culture medium, and the success of many *in-vitro* experiments is dependent on the batch of FBS employed. Therefore, Actovegin can be viewed as a highly controlled and approved form of FBS with an excellent clinical track record for use in human participants.



Figure 1: Actovegin Solution for injection

As noted above, the active component(s) and mechanisms of action of Actovegin have yet to be identified. There is limited supporting evidence concerning the role it might play in the treatment of muscle injuries, and there is no objective evidence pertaining to its properties as an ergogenic aid. Several published clinical studies have investigated its role in muscle injuries with promising results [10,15]. Anecdotally, an unpublished case series with Dr. Hans-Wilhelm Müller-Wohlfahrt's Actovegin, that used a mixture injection regimen, seems to have produced encouraging results, and many high-profile athletes have endorsed the use of Actovegin for the treatment of muscle injuries. Recently, Lee et al reported on the effects of standalone Actovegin injection therapy, which reduced return to play time in injured, professional footballers[10].

Recent controversies on Actovegin

Actovegin has recently received a great deal of media attention in the field of Sports Medicine. In addition to its use in the treatment of injury, many anecdotal testimonies have suggested that Actovegin is ergogenic, and has the potential to improve athletic performance. In December 2000 the International Olympic Committee (IOC) banned Actovegin under the classification of blood-doping agents. However, two months later the IOC lifted the ban as no indisputable evidence demonstrated that Actovegin had ergogenic properties[21]. In a study with 567 diabetic patients, no improvement of muscle strength or condition was found after treatment with Actovegin infusion for 160 days [24]. A more recent study by Lee et al[9] has provided evidence that Actovegin does not have the potential to enhance athletic performance. These investigators performed a blinded, crossover peak aerobic capacity study in healthy human participants with intravenous Actovegin compared to placebo saline solution as well as a baseline control. No significant differences were observed in peak values for aerobic power, blood lactate concentration and blood glucose concentration. Additionally, values of gross and net efficiency, and calorific energy equivalents associated with VO_2 were similar[9]. Their results, therefore, confirmed that a maximum, permitted intravenous dose of Actovegin did not improve human peak aerobic capacity[9]. Currently, neither intravenous nor intramuscular injections of Actovegin are prohibited in or out of competition according to the latest search in the Global Drug Reference Online, which is approved by UK Anti-Doping (UKAD), the Canadian Centre for Ethics in Sport (CCES), the United States Anti-Doping Agency (USADA) and WADA [3,22].

Recent science on Actovegin

As a deproteinised hemodialysate, Actovegin does not contain peptide, growth factors or hormone-like substances[17]. Many studies have attempted to identify the active ingredients in Actovegin, but have been unsuccessful. Studies *in vitro* have suggested that Actovegin promotes oxidative metabolism and shifts the redox-balance of the cells in the direction of oxidized substrates, which might protect against hypoxic cell injury[17]. The most important goal of any post-ischaemic therapeutic strategy is the early interruption of the process of cell-damaging events and, ultimately, the avoidance of cell death. Because Actovegin promotes oxidation and energy production, its efficacy was assumed to benefit

post-ischaemic metabolic events. However, current experimental results from a series of studies with human macrophages by the authors using RT-PCR and flow cytometry have tentatively demonstrated a possible role of Actovegin as an anti-inflammatory agent: this is consistent with the finding that Actovegin can reduce the recovery time in mild muscle injuries. Furthermore, incubation of human muscle biopsies with Actovegin resulted in the up-regulation of a number of genes including the anti-apoptotic gene TNFRSF1b. More research would be required to ascertain the biological roles of Actovegin in inflammation and cell survival, but these authors' work has indicated additional roles of Actovegin not directly related to cellular metabolism.

Søndergård et al suggested in their *in vitro* study with human skeletal tissue, that Actovegin can affect mitochondrial oxidative function which is similar to many other *in vitro* studies with different cell types. However, they also made unsubstantiated, speculative claims that this finding could be translated to performance enhancement in humans. The muscle cells in their experiment were treated with a cocktail of chemicals as well as a cytotoxic detergent, saponin, which damages the cells' membrane[19]. Saponin is extremely poisonous to marine creatures, and it can be used as a cytotoxic chemotherapy drug in the treatment of cancers with major side effects[20]. It stimulates both the Th1 immune response and the production of cytotoxic T-lymphocytes, with the serious side-effects of haemolysis of the cells[20]. Clinically, saponin has been used in clinical trials but toxicity associated with sterol complexation remains a major problem[18,20]. Therefore, the experiment performed by Søndergård et al should be viewed as an *in vitro* cell membrane injury study, similar to the scenario of grade I or II muscle injuries, but most certainly should not be interpreted as a performance-based study [19]. As mentioned earlier, work *in vivo* by Lee et al[9] has shown Actovegin did not improve human peak aerobic capacity. Therefore, the *in vitro* finding from Søndergård et al [19] will not necessarily translate to improve performance in terms of aerobic capacity in humans. Nevertheless, results from this study were interesting as they suggested Actovegin had an effect on injured human muscle tissue, which further supports the clinical use of intramuscular Actovegin injections therapy for injuries as used by Lee et al in their clinical study using a group of professional footballers[10].

Although the exact mechanism of action of this biological drug is yet to be fully understood, recent *in vitro* studies suggest that it has a positive effect on different injured cell types ranging from neuroblastoma cells[23], neutrophils[5] and renal cells[6]. It is clear that Actovegin is not a performance enhancing substance, but has an excellent profile to promote cell repair[1,8]. Further scientific effort of this drug should, therefore, be focused on its application in clinical medicine such as the ARTEMIDA study in patients with post-stroke cognitive impairment[4], wound healing and in the treatment of skeletal muscle injuries[1].

Injection therapy with Actovegin for soft tissue injuries

The use of intramuscular Actovegin injections in the treatment of muscle tears was first published by Pfister and Koller[15]. Their partially blinded, case control study included 103 patients, and demonstrated a reduction in recovery time from 8.3 weeks for the control group to 5.5 weeks in their treatment group[15]. However, patients in this study were recruited from a wide variety of sports and at different competitive levels. A criticism of this study relates to the fact that the treatment regimen and rehabilitation protocols employed were not fully standardised, and Actovegin was mixed with local anaesthetics before being injected; it is, therefore, possible that this would have altered the pharmacodynamics and pharmacokinetics of the drug. The final outcomes were based on subjective observations made by patients and clinicians, and there was no objective pre-injury data to compare outcome characteristics to. Lee et al[10] published a study associated with the intramuscular injection of Actovegin used to treat grade I hamstring injuries. Players in the Actovegin treatment group were able to return to play 8 days earlier compared to physiotherapy alone ($P = 0.033$)[10]. The patients in this study were professional football players from the same club, hence their physical fitness was comparable and the rehabilitation protocol used was standardised[10].

It is evident, that Actovegin has been clinically used for more than 60 years, and it is evident that the oral, topical, intravenous and intramuscular administration of the drug is safe[1]. Many official governing bodies including WADA, UKAD, CCES and USADA do not prohibit its use. However, it should be noted that Actovegin is not on the British National Formulary and

Medicines and Healthcare products Regulatory Agency in the UK, and the Food and Drug Administration in the USA has not approved its use.

Conclusion

The career lifespan of a professional athlete is often short lived, and a shortened recovery time could translate to increased game play and benefit to the team and club. Due to the unique relationship between sports physicians and athletes, individuals are often under pressure to seek the latest “active” or “cutting edge” treatments[2], and athletes are often not interested in being part of a Clinical Trial. Therefore, it is not always possible to recruit a large sample of participants who are professional athletes. There is also much publicity about the use of Actovegin as an ergogenic aid, but such assumptions are founded on speculative and questionable anecdotal evidence. Actovegin is not licensed to treat muscle or soft tissue injuries, and the evidence relating to its effectiveness in this regard is limited. Critics have suggested that Actovegin is nothing more than “snake oil”[2]. Nevertheless, there is published evidence demonstrating its potential for clinical efficacy and safety [4,10,24].

Sport-related muscle injuries are very common, and result in significant morbidity and time lost from training and competitions. Recently, a number of novel treatment options have appeared in the market place. The use of platelet-rich plasma (PRP) and Actovegin has attracted significant interest in Sports Medicine. Although evidence is limited for both of these substances, PRP has received many so-called “expert opinions” and its use has been encouraged. In contrast, views associated with the use of Actovegin are somewhat more tainted, but with the exception of subjective, anecdotal opinion, there is no clear evidence that Actovegin has any ergogenic qualities. Evidence based medicine is an important aspect in modern medicine; we must not reject treatment base on limited evidence. However, we should be cautious in our consideration and interpretation of available evidence, strike a balance between potential risk and benefit associated with treatment, and tailor the use of any therapeutic intervention to the individual athlete’s needs.

References:

1. Buchmayer F, Pleiner J, Elmlinger MW, Lauer G, Nell G, Sitte HH. Actovegin(R): a biological drug for more than 5 decades. *Wien Med Wochenschr* 2011;161:80-88
2. Franklyn-Miller A, Etherington J, McCrory P. Sports and exercise medicine--specialists or snake oil salesmen? *Br J Sports Med* 2011;45:83-84
3. Global DRO. 2016. The Global Drug Reference Online [Online]. Available: <http://www.globaldro.com/Home> [Accessed 17/5/2016 2016].
4. Guekht A, Skoog I, Korczyn AD, Zakharov V, Eeg M, Vigonius U. A Randomised, Double-Blind, Placebo-Controlled Trial of Actovegin in Patients with Post-Stroke Cognitive Impairment: ARTEMIDA Study Design. *Dement Geriatr Cogn Dis Extra* 2013;3:459-467
5. Gulevsky AK, Moiseyeva NN, Gorina OL. Influence of low molecular (below 5 KD) fraction from cord blood and actovegin on phagocytic activity of frozen-thawed neutrophils. *Cryo letters* 2011;32:131-140
6. Gulevsky AK, Trifonova AV, Lavrik AA. Stimulating effect of cord blood fraction below 5 kDa and actovegin on cell growth of permanent cell lines. *Cell and Tissue Biology* 2011;5:144-150
7. Laupheimer MW, Silva AD, Hemmings S. Injection therapies in muscle injuries: A systematic review. *Int Musculoskelet Med* 2015;37:170-177
8. Lee P, Kwan A, Nokes L. Actovegin--Cutting-edge sports medicine or "voodoo" remedy? *Curr Sports Med Rep* 2011;10:186-190
9. Lee P, Nokes L, Smith PM. No effect of intravenous Actovegin(R) on peak aerobic capacity. *Int J Sports Med* 2012;33:305-309
10. Lee P, Rattenberry A, Connelly S, Nokes L. Our experience on Actovegin, is it cutting edge? *Int J Sports Med* 2011;32:237-241
11. Maffulli N. Republished editorial: Autologous blood products in musculoskeletal medicine. *Br J Sports Med* 2014;48:1392-1393
12. Moraes VY, Lenza M, Tamaoki MJ, Faloppa F, Belloti JC. Platelet-rich therapies for musculoskeletal soft tissue injuries. *The Cochrane database of systematic reviews* 2014;4:CD010071
13. Mosca MJ, Rodeo SA. Platelet-rich plasma for muscle injuries: game over or time out? *Curr Rev Musculoskelet Med* 2015;8:145-153
14. Orchard JW, Best TM, Mueller-Wohlfahrt HW, Hunter G, Hamilton BH, Webborn N, Jaques R, Kenneally D, Budgett R, Phillips N, Becker C, Glasgow P. The early management of muscle strains in the elite athlete: best practice in a world with a limited evidence basis. *Br J Sports Med* 2008;42:158-159
15. Pfister A, Koller W. [Treatment of fresh muscle injury]. *Sportverletz Sportschaden* 1990;4:41-44
16. Reurink G, Goudswaard GJ, Moen MH, Weir A, Verhaar JA, Bierma-Zeinstra SM, Maas M, Tol JL, Dutch HITsI. Rationale, secondary outcome scores and 1-year follow-up of a randomised trial of platelet-rich plasma injections in acute hamstring muscle injury: the Dutch Hamstring Injection Therapy study. *Br J Sports Med* 2015;49:1206-1212
17. Schonwald D, Sixt B, Machicao F, Marx E, Haedenkamp G, Bertsch S. Enhanced proliferation of coronary endothelial cells in response to growth factors is synergized by hemodialysate compounds in vitro. *Res Exp Med (Berl)* 1991;191:259-272
18. Skene CD, Sutton P. Saponin-adjuvanted particulate vaccines for clinical use. *Methods* 2006;40:53-59

19. Sondergard SD, Dela F, Helge JW, Larsen S. Actovegin, a non-prohibited drug increases oxidative capacity in human skeletal muscle. *Eur J Sport Sci* 2016;1-7
20. Sun HX, Xie Y, Ye YP. Advances in saponin-based adjuvants. *Vaccine* 2009;27:1787-1796
21. Tsitsimpikou C, Tsiokanos A, Tsarouhas K, Schamasch P, Fitch KD, Valasiadis D, Jamurtas A. Medication use by athletes at the Athens 2004 Summer Olympic Games. *Clin J Sport Med* 2009;19:33-38
22. World Anti Doping Agency. 2016. Prohibited List 2016 [Online]. Available: <https://www.wada-ama.org/en/what-we-do/prohibited-list> [Accessed 17/05/2016 2016].
23. Yurinskaya MM, Vinokurov MG, Grachev SV, Astashkin EI. Actovegin reduces the hydrogen peroxide-induced cell apoptosis of SK-N-SH neuroblastoma by means of p38MAPK and PI-3K inhibition. *Dokl Biol Sci* 2014;456:215-217
24. Ziegler D, Movsesyan L, Mankovsky B, Gurieva I, Abylaiuly Z, Stokov I. Treatment of symptomatic polyneuropathy with actovegin in type 2 diabetic patients. *Diabetes Care* 2009;32:1479-1484